Scale Up

Nov 01, 2018
BioPharm International
Advanced therapy medicinal products pose unique manufacturing challenges that will require appropriate and thoughtful facility design and equipment.
Nov 01, 2018
BioPharm International
Platform processes have improved monoclonal antibody scale-up. Can they do the same for personalized therapies?
Oct 23, 2018
Bioconjugation requires aseptic manufacturing and containment for cytotoxic payloads.
Oct 01, 2018
BioPharm International
The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.
Sep 20, 2018
By BioPharm International Editors
The CHF 400-million (US$416-million) investment in Lonza's biopark in Visp, Switzerland, will expand Ibex Solutions with two new offerings, drug substance development and drug substance and drug product manufacturing.
Sep 20, 2018
By BioPharm International Editors
The CHF 400-million (US$416-million) investment in Lonza's biopark in Visp, Switzerland, will expand Ibex Solutions with two new offerings, drug substance development and drug substance and drug product manufacturing.
Aug 24, 2018
By BioPharm International Editors
The new Testa Center in Uppsala, Sweden is a collaborative test bed offering biotechnology equipment from GE Healthcare for process development.
Aug 01, 2018
BioPharm International
Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.
Jul 19, 2018
By BioPharm International Editors
The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.
Jul 01, 2018
BioPharm International
Late-stage and commercial biomanufacturing pose a challenge to cell-culture processing.
native1_300x100
lorem ipsum